Somatic Variant: TET2

TET2 mutations are associated with an increased sensitivity to hypomethylating agents, such as AzaC. This study of 86 patients with MDS and AML observed a response rate of 86% in patients with mutated TET2 versus 45% in patients that were wild type, with a reported p-value of 0.007.

Citations:

• Itzykson R, Kosmider O, Cluzeau T, et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia. 2011;25(7):1147-1152